Article

Health officials scramble to find source of fungal keratitis cases

Atlanta-With a growing list of states reporting suspectedcases of an uncommon fungal keratitis, the Centers for DiseaseControl and Prevention (CDC) and other U.S. health authoritiescontinue to search for the cause of an apparent outbreak of therare fungal infection among soft contact-lens wearers.

Atlanta-With a growing list of states reporting suspected cases of an uncommon fungal keratitis, the Centers for Disease Control and Prevention (CDC) and other U.S. health authorities continue to search for the cause of an apparent outbreak of the rare fungal infection among soft contact-lens wearers.

As of late April, the CDC had confirmed 54 cases of keratitis caused by the Fusarium fungus over the past 10 months, with eight possible cases and 114 more still under investigation. The total of 176 suspected cases are being reported from 26 states and Puerto Rico. Eight patients have required corneal transplants.

The outbreak is baffling medical experts because it seems to have appeared suddenly-in the United States, Singapore, and Hong Kong-with little indication as to its cause.

The majority of confirmed cases are being linked to the use of Bausch & Lomb's ReNu with MoistureLoc Multi-Purpose Solution, although some have involved other brands. Of the first 30 confirmed cases, 28 patients wore soft contact lenses, and 26 of those remembered using Bausch & Lomb's ReNu brand contact lens solution in the month before infection. The most current figures were unavailable at press time.

However, thorough testing of the ReNu bottles used in confirmed cases-as well as the Greenville, SC, plant where the product is manufactured-has failed to find the source for the fungal keratitis.

"We have gone to the point of retrieving open bottles from consumers who have had complications, who have had a Fusarium infection. We have tested that product, and in every case the open product is still efficacious," Zarella said.

Meanwhile the FDA and the CDC are continuing joint inspections of the Green-ville plant, which ships ReNu with MoistureLoc to the United States, Southeast Asia, and Korea. FDA officials cautioned in an April 21 update that extensive microbiological testing might take up to 1 month to analyze fully. A CDC researcher said the situation is receiving intense scrutiny by his agency.

Dr. Chang urged ophthalmologists to consider fungal keratitis early on when presented with symptoms of an ocular infection and called this apparent outbreak "the largest I have personally experienced."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.